Rhizomelic pseudopolyarthritis (RPA) is a rare and hereditary inflammatory disease characterized by symmetrical joint involvement, primarily in the extremities. Almost all cases of the disease occur in children, accompanied by joint pain, swelling, redness of the skin over the affected areas, and impaired functionality. A unique feature of RPA is that it mainly affects the distal or proximal parts of the extremities, causing significant changes in joint morphology. Although the disease is autoimmune in nature, its pathogenesis is not fully understood, which complicates diagnosis and treatment. Therapeutic measures are aimed at reducing inflammation and relieving symptoms, but joint recovery may be difficult.
History of the disease and interesting historical facts
Rhizomelic pseudopolyarthritis was first described in the early 20th century, when doctors noted characteristic clinical manifestations in children who were resistant to traditional treatment. In the 1950s, specialists proposed the concept of a genetic predisposition to the disease, which became the basis for further research. Some historical facts emphasize the importance of early diagnosis: one of the first publications reported that the lack of adequate treatment can lead to a significant deterioration in the functional state and mobility of joints. In the 1970s, the first treatment methods were introduced, including non-steroidal anti-inflammatory drugs, which significantly improved the quality of life of patients with eating disorders.
Epidemiology
Rhizomelic pseudopolyarthritis occurs mainly in children aged 1 to 5 years, but cases in adolescents and adults are also known. According to various studies, the prevalence of ED is approximately 1 in 100,000 children. The low prevalence of the disease makes it difficult to study and leads to the lack of large cohorts for reliable studies. Studies in different regions show that the predisposition to ED may vary depending on the ethnic group. Couples with a genetic predisposition to ED have a higher chance of having children with this disease.
Genetic predisposition to this disease
The discovery of mutations in certain genes, such as ATP5A1 and HSP70, which are involved in cellular apoptosis and stress management, has provided insight into the genetic mechanisms of eating disorders. Looking at mutations in these genes allows us to infer the hereditary nature of the disease. Several clinical trials have found a link between certain gene alleles and an increased likelihood of developing eating disorders in certain populations. It has been established that a reduction in environmental conditions and hereditary predisposition can lead to the development of the disease in the presence of the necessary triggers, such as infections or stressful situations.
Risk factors for the development of this disease
The main risk factors that contribute to the development of rhizomelic pseudopolyarthritis include:
- Use of certain medications during pregnancy.
- The presence of infectious diseases, especially viral ones, in children.
- Genetic predisposition confirmed in first-degree relatives.
- History of existing autoimmune diseases.
- Environmental factors such as pollution.
Each of these factors can not only increase the likelihood of the disease, but also lead to its less favorable course, which requires special attention from doctors and parents.
Diagnosis of this disease
Diagnosis of eating disorders includes complex measures based on clinical manifestations of the disease. The main symptoms that should alert the doctor include:
- Joint pain, especially in the knee and elbow joints.
- Swelling and redness of the skin in the area of the affected joints.
- Increase in body temperature.
- Limited joint mobility.
Laboratory tests such as complete blood count, biochemical analysis and inflammation markers can confirm the presence of inflammatory processes in the body. Radiological examinations, in particular X-rays, reveal changes in the joint structures such as erosion and osteoporosis. It is also important to conduct a differential diagnosis with other joint diseases such as juvenile idiopathic arthritis and ankylosing spondylitis.
Treatment
Treatment for rhizomelic pseudopolyarthritis may vary depending on the severity of the disease and the age of the patient. The main areas of therapy include:
- General treatment: rest, physiotherapy.
- Pharmacological treatment: use of non-steroidal anti-inflammatory drugs (NSAIDs) to relieve pain and reduce inflammation.
- Surgical treatment: In severe cases, surgery such as arthroplasty may be required.
- Other treatments: The use of biologic drugs such as tumor necrosis factor (TNF) inhibitors has been supported in some clinical trials.
An individual approach to each patient is important, depending on the characteristics of the clinical picture and health status.
List of drugs used to treat this disease
Among the drugs often used to treat rhizomelic pseudopolyarthritis, the following can be distinguished:
- Ibuprofen
- diclofenac
- Naproxen
- Methotrexate
- etanercept
The selection of drugs should be carried out in accordance with the individual indicators and condition of the patient.
Disease monitoring
Monitoring patients with rhizomelic pseudopolyarthritis requires regular monitoring of the joints and general condition of the body. The main control stages include:
- Regular check-ups with a doctor to assess joint function and the presence of pain.
- Laboratory tests to monitor inflammatory markers.
- Conducting periodic radiological examinations to assess changes in bone tissue.
The prognosis depends on early detection, adequate treatment, and individual patient characteristics. Complications may include the development of chronic pain syndrome and flattening of the joints.
Age-related features of the disease
Rhizomelic pseudopolyarthritis may manifest itself differently depending on the patient's age group. In children, the disease often starts acutely, accompanied by pronounced clinical symptoms. In adolescents and adults, the course of the disease may be more latent, which complicates diagnosis. With age, as the disease progresses, changes in the functionality of the joints are possible, which require a revision of treatment methods.
Questions and Answers
- What are the main symptoms of rhizomelic pseudopolyarthritis? The main symptoms include joint pain, swelling, redness of the skin over the joints and limited mobility.
- What diagnostic methods are used to detect this disease? Diagnosis includes clinical examination, laboratory tests, radiological examinations and differential diagnosis with other joint diseases.
- What are the main approaches to treating rhizomelic pseudopolyarthritis? Treatment may include NSAIDs, physical therapy, surgery, and biologic medications.
- What is the role of genetic predisposition in the development of the disease? The presence of certain mutations in genes may increase the likelihood of developing rhizomelic pseudopolyarthritis in children with a genetic predisposition.
- How often should I be monitored for this condition? Monitoring should be performed regularly, as recommended by the treating physician, with target control stages every 3-6 months.
